Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Sponsor: Rennes University Hospital
Summary
Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis
Official title: Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2010-03
Completion Date
2023-11
Last Updated
2026-06-15
Healthy Volunteers
No
Conditions
Interventions
mitoxantrone - immunomodulator
mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
natalizumab
monthly natalizumab during 3 years
Locations (2)
CHU Cavale Blanche
Brest, France
CHU Rennes
Rennes, France